Search

Your search keyword '"Dao Trong, Philip"' showing total 11 results
Start Over Author "Dao Trong, Philip" Search Limiters Full Text
11 results on '"Dao Trong, Philip"'

3. Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580

Author

Fermi, Valentina, primary, Warta, Rolf, additional, Wöllner, Amélie, additional, Lotsch, Catharina, additional, Jassowicz, Lena, additional, Rapp, Carmen, additional, Knoll, Maximilian, additional, Jungwirth, Gerhard, additional, Jungk, Christine, additional, Dao Trong, Philip, additional, von Deimling, Andreas, additional, Abdollahi, Amir, additional, Unterberg, Andreas, additional, and Herold-Mende, Christel, additional

Published
2023
Full Text
View/download PDF

11. Large-Scale Drug Screening in Patient-Derived IDH mut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.

Author

Dao Trong P, Jungwirth G, Yu T, Pusch S, Unterberg A, Herold-Mende C, and Warta R

Subjects
Annexin A5 metabolism, Antineoplastic Agents pharmacology, Brain Neoplasms enzymology, Brain Neoplasms genetics, Brain Neoplasms pathology, Cell Death drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Glioma enzymology, Glioma genetics, Glioma pathology, Humans, Inhibitory Concentration 50, Propidium metabolism, Reproducibility of Results, United States, United States Food and Drug Administration, Antineoplastic Agents therapeutic use, Brain Neoplasms drug therapy, Drug Approval, Drug Screening Assays, Antitumor, Glioma drug therapy, Isocitrate Dehydrogenase genetics, Mutation genetics, Neoplastic Stem Cells pathology
Abstract

The discovery of the isocitrate dehydrogenase (IDH) mutation in glioma led to a paradigm shift on how we see glioma biology. Difficulties in cultivating IDH mutant glioma stem cells (IDH mut GSCs) resulted in a paucity of preclinical models in IDH mut glioma, limiting the discovery of new effective chemotherapeutic agents. To fill this gap, we used six recently developed patient-derived IDH mut GSC lines and performed a large-scale drug screening with 147 Food and Drug Administration (FDA)-approved anticancer drugs. GSCs were subjected to the test compounds for 72 h in concentrations ranging from 0.0001 to 1 µM. Cell viability was assessed by CellTiterGlo and the induction of apoptosis by flow cytometry with Annexin V/propidium iodide staining. The initial screen was performed with two IDH mut GSC lines and identified seven drugs (bortezomib, carfilzomib, daunorubicin, doxorubicin, epirubicin, omacetaxine, plicamycin) with a substantial antiproliferative activity, as reflected by half maximal inhibitory concentrations (IC 50 ) below 1 µM and maximum inhibitory effects (E max ) below 25%. These findings were validated in an additional four IDH mut GSC lines. The candidate drugs, of which plicamycin and omacetaxine are known to cross the blood brain barrier, were used for subsequent cell death analyses. A significant induction of apoptosis was observed at IC 50 values of the respective drugs. In summary, we were able to identify seven FDA-approved drugs that should be further taken into clinical investigations for the treatment of IDH mut gliomas.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results